Overview

Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction

Status:
Withdrawn

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

This study aims to investigate the effects of treatment with intravenous ferric carboxymaltose on exercise tolerance measured as VO2peak in patients with HFpEF and iron deficiency, compared to placebo.

Phase:

Phase 4

Details

Lead Sponsor:

Cantonal Hosptal, Baselland

Collaborator:

Clinical Trial Unit, University Hospital Basel, Switzerland